





1/44

Figure 1**Red blood cell lysis in donor A after incubation
with PMAA-Na in RPMI****Figure 1a****Red blood cell lysis in donor C after incubation
with PMAA-Na in RPMI****Figure 1b**

2/44

Figure 1 cont.**Figure 1c**


3/44

Figure 2


4/44

Figure 3

Lack of toxicity of PMAA-Na on primary human monocyte-derived-macrophages

**Figure 3a**


Lack of toxicity of PMAA-Na on primary human peritoneal macrophages

**Figure 3b**


5/44

Figure 4

Release of MIP-1 β from human peritoneal macrophages by endotoxin free PMAA-Na (500 μ g/ml) after 36 h from a single donor A

**Figure 4a**


Release of MIP-1 β from human peritoneal macrophages by endotoxin free PMAA-Na (500 μ g/ml) after 36 h from a single donor B

**Figure 4b**

6/44

Figure 4 cont.


Release of MIP-1 β from human peritoneal macrophages by endotoxin free PMAA-Na (500 μ g/ml) after 36 h from a single donor C

**Figure 4c**


7/44

Figure 5

Release of TNF- α from human peritoneal macrophages by endotoxin free PMAA-Na (2,000 μ g/ml) after 36 h from a single donor A

**Figure 5a**




Release of TNF- α from human peritoneal macrophages by endotoxin free PMAA-Na (500 μ g/ml) after 36 h from a single donor B

**Figure 5b**




8/44

Figure 6

Release of chemokines and cytokines from single donor human peritoneal macrophages incubated with media control (□) or with PMAA-Na at 500 µg/ml (■) for 36 h

**Figure 6a****Figure 6b****Figure 6c**


9/44

Figure 6 cont.**Figure 6d****Figure 6e****Figure 6f**


10/44

Figure 7

Release of MIP-1 β from human monocyte derived macrophages by
endotoxin free PMAA-Na after 36 h from a single donor A

**Figure 7a**


Release of MIP-1 β from human monocyte derived macrophages by
endotoxin free PMAA-Na after 36 h from a single donor B

**Figure 7b**

11/44

Figure 7 cont.


Release of MIP-1 β from human monocyte derived macrophages by endotoxin free PMAA-Na after 36 h from a single donor C

**Figure 7c**


12/44

Figure 8

Release of MIP-1 β from human peritoneal macrophages by PMAA-Na (500 μ g/ml) but not by commercially available PM AA-Na (500 μ g/ml) after 36 h from donor A

**Figure 8a**


Release of MIP-1 β from human peritoneal macrophages by PMAA-Na (500 μ g/ml) but not by commercially available PM AA-Na (500 μ g/ml) after 36 h from donor A

**Figure 8b**


13/44

Figure 9

Release of TNF- α from human peritoneal macrophages by PMAA-Na (500 μ g/ml) but not by commercially available PM AA-Na (500 μ g/ml) after 36 h from donor A

**Figure 9a**


Release of TNF- α from human peritoneal macrophages by PMAA-Na (500 μ g/ml) but not by commercially available PM AA-Na (500 μ g/ml) after 36 h from donor A

**Figure 9b**


14/44

Figure 10


Red blood cell lysis in donor A after a 1 hour incubation in RPMI

**Figure 10a**

Red cell lysis in donor B after a 1 hour incubation in RPMI

**Figure 10b**


Red blood cell lysis in donor C after a 1 hour incubation in RPMI

**Figure 10c**


15/44

Figure 11


Red blood cell lysis in donor A after a 6 hour incubation in RPMI

**Figure 11a**

Red blood cell lysis in donor B after a 6 hour incubation in RPMI

**Figure 11b**


Red cell lysis in donor C after a 6 hour incubation in RPMI

**Figure 11c**


16/44

Figure 12


Red blood cell lysis in donor A after a 24 hour incubation in RPMI

**Figure 12a**

Red cell lysis in donor C after a 24 hour incubation in RPMI

**Figure 12b**


Red blood cell lysis in donor C after a 24 hour incubation in RPMI

**Figure 12c**

17/44

Figure 13


Red blood cell lysis in single donor after incubation with the amphotericin B - PMAA-Na preparation in RPMI




18/44

Figure 14


Lack of toxicity of the amphotericin B - PMAA-Na preparation
after 1 day of culture with PBMN cells (n=3)

**Figure 14a**

Lack of toxicity of the amphotericin B - PMAA-Na preparation
after 2 days of culture with PBMN cells (n=3)

**Figure 14b**


Lack of the toxicity of amphotericin B - PMAA-Na preparation
after 6 days of culture with PBMN cells (n=2)

**Figure 14c**


19/44

Figure 15



Toxicity of the amphotericin B - PMAA-Na preparation after 2 days
of culture with monocyte derived macrophages

**Figure 15a**



Toxicity of the amphotericin B - PMAA-Na preparation after
3 days of culture with monocyte derived macrophages

**Figure 15b**

20/44

Figure 16Viability of *Leishmania mexicana* promastigotes after 2 days**Figure 16a**Viability of *Leishmania mexicana* promastigotes after 2 days**Figure 16b**


21/44

Figure 16 cont.**Figure 16c****Figure 16d**


22/44

Figure 17



Viability of *Leishmania donovani* promastigotes
after 2 days

**Figure 17a**

Viability of *Leishmania donovani* promastigotes
after 2 days

**Figure 17b**


23/44

Figure 17 cont.**Figure 17c****Figure 17d**


24/44

Figure 18

Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 18a**


Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 18b**


25/44

Figure 18 cont.

Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 18c**


Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 18d**


26/44

Figure 19

**Inhibition of intracellular *Leishmania mexicana* amastigote growth
by clinical grade amphotericin B in
human monocyte derived macrophages**

**Figure 19a**


**Inhibition of intracellular *Leishmania mexicana* amastigote growth
by Ambisome (Gilead Sciences) in
human monocyte derived macrophages**

**Figure 19b**

27/44

Figure 20

Inhibition of intracellular *Leishmania mexicana* amastigote growth in human macrophages by amphotericin B - PMAA-Na compared to AmBisome




— amphotericin B - PMAA-Na = 0.3 µg/ml
IC₅₀
..... AmBisome (Gilead Sciences): IC₅₀ = 1.7 µg/ml


28/44

Figure 21

Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 21a**


Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 21b**


29/44

Figure 21 cont.

Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 21c**


Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages

**Figure 21d**


30/44

Figure 22

**Inhibition of intracellular *Leishmania donovani* amastigote growth
by clinical grade amphotericin B in
human monocyte derived macrophages**

**Figure 22a**


**Inhibition of intracellular *Leishmania donovani* amastigote growth
by Ambisome (Gilead Sciences) in
human monocyte derived macrophages**

**Figure 22b**

31/44

Figure 23


Release of interferon- γ from human peritoneal macrophags after culture with different compounds for 24 h




32/44

Figure 24


PBMC proliferation after 6 days incubation of the cells of donor A
with the tuberculin PPD - PMAA-Na preparation

**Figure 24a**

PBMC proliferation after 5 days stimulation with antigen
of the cells from donor B

**Figure 24b**


33/44

Figure 25



34/44

Figure 26


Survival of *L. donovani* amastigotes in mouse liver macrophages after intravenous treatment with several different preparations of amphotericin B





35/44

Figure 27**Lack of toxicity of PMAA-Na to single donor red blood cells (n=3)****Figure 27a****Figure 27b**

36/44

Figure 27 cont.**Figure 27c**


37/44

Figure 28**Lack of toxicity of PMAA-NA to single donor PBMCs after a 1 day incubation (n=3)****Figure 28a****Lack of toxicity of PMAA-NA to single donor PBMCs after a 2 day incubation (n=3)****Figure 28b**


38/44

Figure 29

Lysis of red blood cells after incubation with amphotericin B - PMAA-Na stored as a lyophilised powder at 4°C for 4 months (n=2)

**Figure 29a**


Lysis of red blood cells after a 1 h incubation with amphotericin B - PMAA-Na stored in 5% dextrose at 4°C for 7 months

**Figure 29b**


39/44

Figure 30

**Inhibition of *L. mexicana* amastigote growth in human MDMs
after 3 d incubation with amphotericin B - PMAA-Na stored
as a lyophilised powder at 4°C for 4 months**

**Figure 30a**


**Viability of *L. mexicana* promastigotes after 2 d incubation
with amphotericin B - PMAA-Na stored in 5% dextrose at 4°C for 7 months**

**Figure 30b**


40/44

Figure 31

Inhibition of *C. neoformans* var *neoformans* clinical isolate 1 in monocyte derived macrophages after 3 days

**Figure 31a**


Inhibition of *C. neoformans* var *neoformans* NCPF 3003 growth in monocyte derived macrophages after 3 days

**Figure 31b**


41/44

Figure 31 cont.



Inhibition of *C. neoformans* var *gattii* clinical isolate growth in peritoneal macrophages after 3 days

**Figure 31c**

Inhibition of *C. neoformans* var *gattii* clinical in monocytes derived macrophages after 3 days

**Figure 31d**

42/44

Figure 32**Figure 32a****Figure 32b**

43/44

Figure 32 cont.

Viability of *C.neofomans* var *gattii*
NCPF 3216 after 3 days




Figure 32c

Viability of *C.neofomans* var *gattii*
clinical isolate after 3 days






Figure 32d

44/44

Figure 33**Figure 33a****Figure 33b**